Zhao L, Zhu C, Lu M, et al
Current clinical evidence for possible antidepressant effects of GLP-1R agonists Depression is often comorbid with metabolic disorders such as T2DM and obesity and many antidiabetic drugs, which often display neuroprotective and immunomodulatory effect, have demonstrated antidepressant properties in clinical trials
Tirzepatide for Weight Loss: What It Is and Who Its For Tirzepatide was approved by the FDA in 2022 for type 2 diabetes, and in 2023 for weight control for people with obesity or overweight and at least one weight-related condition (like high blood pressure or cholesterol)
Research Article - (2021) Volume 12, Issue 3 Diabetes prevalence is increasing, according to the International Diabetes Federation report in 2013, 382 Millions have diabetes, and the number is expected to rise beyond 592 million by 2035, an increase of approximately 55%
For people in lower income brackets, this can have a profound impact on their lives
12 By embracing these strategies, individuals using GLP-1 medications can optimize their results, minimize discomfort, and build a foundation for a healthier, more empowered future
